Cargando…

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory prospective observational study to compare th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oe, Yuki, Nomoto, Hiroshi, Nakamura, Akinobu, Kuwabara, Saki, Takahashi, Yuka, Yasui, Ayano, Izumihara, Rimi, Miya, Aika, Kameda, Hiraku, Cho, Kyu Yong, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793345/ https://www.ncbi.nlm.nih.gov/pubmed/35097130 http://dx.doi.org/10.1155/2022/5603864

Ejemplares similares

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials
por: Janez, Andrej, et al.
Publicado: (2020)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
por: Minze, Molly G, et al.
Publicado: (2016)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

ODP279 A Case of Nephrogenic Diabetes Insipidus Diagnosed at an Advanced Age in a Female Patient with an AVPR2 Gene Mutation and Skewed×Inactivation
por: Nakata, Kento, et al.
Publicado: (2022)

Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
por: Miya, Aika, et al.
Publicado: (2020)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

ODP332 Maternal Central Diabetes Insipidus Immediately after Delivery, Owing to Vasospasm of the Internal Carotid Artery
por: Yokozeki, Kei, et al.
Publicado: (2022)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring
por: Miya, Aika, et al.
Publicado: (2021)

Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study
por: Sekizaki, Tomonori, et al.
Publicado: (2021)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
por: Aye, Myint M, et al.
Publicado: (2014)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

SUN-179 Prolonged Hypoglycemia from Insulin Degludec
por: Kothari, Vallari, et al.
Publicado: (2019)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
por: Rodbard, H. W., et al.
Publicado: (2016)

Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
por: Harris, Stewart, et al.
Publicado: (2020)

SAT-413 Does Dipeptidyl Peptidase-4 Inhibitor Exacerbate Graves’ Disease?
por: Sekizaki, Tomonori, et al.
Publicado: (2020)

DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin
por: Pei, Yu, et al.
Publicado: (2021)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China
por: Han, Guangxin, et al.
Publicado: (2022)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
por: Haahr, Hanne, et al.
Publicado: (2014)

Insulin degludec aspart: One-year real world experience
por: Kalra, Sanjay, et al.
Publicado: (2016)

Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions
por: Kalra, Sanjay, et al.
Publicado: (2015)

Insulin degludec in the first trimester of pregnancy: Report of two cases
por: Milluzzo, Agostino, et al.
Publicado: (2017)

Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes
por: Henao-Carrillo, Diana Cristina, et al.
Publicado: (2018)

Successful Outcomes with Insulin Degludec in Pregnancy: A Case Series
por: Hiranput, Siwaporn, et al.
Publicado: (2018)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor
por: Oba-Yamamoto, Chiho, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_alpu9q0n453d5mrejdif74kvko